BMRN vs. VRTX: BioMarin Pharmaceutical vs. Vertex Pharmaceuticals Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Vertex Pharmaceuticals (VRTX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Vertex Pharmaceuticals (VRTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BMRN | VRTX |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Vertex Pharmaceuticals Incorporated Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.85 billion USD | 138.71 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | July 24, 1991 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| Total Return (1Y) | 8.82% | 34.89% |
| Total Return (3Y, Annualized) | -12.54% | 14.44% |
| Total Return (5Y, Annualized) | -7.51% | 23.65% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 29.73% |
| Beta (5Y) | 0.24 | 0.29 |
| Max Drawdown (5Y) | -57.64% | -29.07% |
| Avg. Volume (3M) | 2.28M | 1.25M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 1.03 |
| Sortino Ratio (1Y) | 0.23 | 1.68 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Vertex Pharmaceuticals (VRTX) reports 20.80%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.80%
- Max
- 109.18%
- VRTX
- 20.80%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Vertex Pharmaceuticals (VRTX) reports 30.70%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.70%
- VRTX
- 30.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at 26.58% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.57%
- Max
- 83.12%
- VRTX
- 35.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| ROE (TTM) | -0.31% | 20.80% |
| ROA (TTM) | 3.89% | 10.62% |
| Net Margin (TTM) | -0.52% | 30.70% |
| Operating Margin (TTM) | 26.58% | 35.57% |
| Gross Margin (TTM) | 53.21% | 54.81% |
Growth
Revenue Growth
Both BioMarin Pharmaceutical (BMRN) at 12.87% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.
Growth Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | 8.90% |
| Revenue Growth (3Y CAGR) | 15.40% | 10.35% |
| EPS Growth (YoY) | -18.55% | -- |
| EPS Growth (3Y CAGR) | 33.89% | 6.12% |
Financial Strength
Current Ratio (MRQ)
Both BioMarin Pharmaceutical (BMRN) at 2.44 and Vertex Pharmaceuticals (VRTX) at 2.34 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.34
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VRTX
- 2.34
- Min
- 0.10
Debt / Equity (MRQ)
Vertex Pharmaceuticals (VRTX) at 0.31 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- VRTX
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 2.34 |
| Debt / Equity (MRQ) | 0.67 | 0.31 |
| Net Debt / EBITDA | 4.04 | 0.03 |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- VRTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- VRTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Vertex Pharmaceuticals (VRTX) trades at 35.21 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.21
- Max
- 85.34
- Q3
- 43.46
- VRTX
- 35.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Vertex Pharmaceuticals (VRTX) at 10.71 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.71
- Max
- 58.18
- Q3
- 25.77
- VRTX
- 10.71
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Vertex Pharmaceuticals (VRTX) at 6.63 carries an above-peer premium to book — VRTX is pricier on assets.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.63
- Max
- 13.53
- VRTX
- 6.63
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | VRTX |
|---|---|---|
| P/E Ratio (TTM) | -- | 35.21 |
| P/S Ratio (TTM) | 2.97 | 10.71 |
| P/B Ratio (MRQ) | 1.73 | 6.63 |
| Free Cash Flow Yield (TTM) | -0.15% | 1.69% |